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Abstract Dietary algae have been reported to decrease HIV
viral fusion/entry and replication and increase immune re-
sponse, suggesting that regular consumption of algae by people
in Japan, Korea, and Chad could be an important factor in their
relatively low HIV/AIDS rates. Five antiretroviral-naïve people
with HIV (three females, two males; five African Americans)
living in Columbia SC participated in the phase I study of acute
t o x i c i t y .S u b j e c t sw e r er a n d o m l ya s s i g n e dt o5gd a y
-1 brown
seaweed (Undaria pinnatifida), Spirulina (Arthrospira platen-
sis), or a combination of both. Endpoints included HIV viral
load, complete blood count (CBC), metabolic and lipid panel,
and quality of life questionnaire data. When no short-term
toxicities were observed, six additional subjects (four females,
two males; five African Americans, one Latina) were recruited
to further evaluate short- and long-term toxicities (phase II). No
adverse effects were observed for the 11 subjects in the phase I
trial, and quality of life indicators improved at 3 weeks. No
significant changes were observed in CBC, metabolic or lipid
panel analyses. CD4 cells (milliliters) and HIV-1 viral load
remained stable over the first 3-month phase II study period.
One subject continued in the study for 13 months and had
clinically significant improvement in CD4 (>100 cells mL
−1)
and decreased HIV viral load of 0.5 log10. Our pilot data
suggest that Undaria, Spirulina, and a combination of both
were nontoxic and over time may improve clinical endpoints of
HIV/AIDS.
Keywords CD4Tcells.HIVviralload.Clinicaltrial.
Qualityoflife.Undariapinnatifida.Seaweed.Spirulina
Introduction
Dietary chemoprevention of HIV/AIDS is an attractive con-
cept. In the best of worlds, everyone with AIDS would have
access to pharmaceutical antiretroviral (ARV) medications,
but in reality, only 5 million of 34 million people living with
HIV/AIDS currently have access to ARV treatment
(UNAIDS 2011). Additionally, ARV is not curative and is
both expensive and associated with significant side effects
including heart disease and dementia for long-time users
(Payne et al. 2011), and drug resistance is an increasingly
common problem.
Dietary algae may be an important factor in explaining
geographic differences.Seaweedsareconsumeddaily by most
people in Japan and Korea, but only infrequently in other
countriesoftheworld.RatesofHIV/AIDSinJapanandKorea
have remained stable and extremely low over the last 30 years
(<0.1%) compared to rates in the USA (0.6%) (UNAIDS
2011). Although seaweed is rarely consumed in Africa, some
tribal groups in Chad have traditionally consumed the blue-
green alga Arthrospira platensis (Spirulina)a sp a r to ft h e i r
daily cuisine (Abdulqader et al. 2000). HIV/AIDS rates in
Chad are high (5.1%) compared to Asia, but have remained
lower than in several nearby countries, despite poverty and
decades of civil unrest (UNAIDS 2011).
Algae contain a wide variety of bioactive compounds.
Lacking an immune system, algae have developed elaborate
chemical defense compounds against bacteria, viruses, and
fungi, which pose significant threats to algae. It has been
estimated that a milliliter of seawater contains 10
7 viruses,
10
6 bacteria, and 10
3 fungal cells (Rheinheimer 1992). Few
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DOI 10.1007/s10811-011-9766-0in-depth studies have been conducted, but work of Kubanek
and her colleagues have identified more than 20 different
antimicrobial compounds from the surfaces of two common
macroalga (Kubanek et al. 2003; Lane et al. 2009). These
compounds have been shown to be effective against infec-
tious and pathogenic microbes and show promise against
some human diseases. The presence of similar compounds
on other seaweeds may help explain the observed in vitro
and in vivo anti-HIV activities of several algae. Possible
mechanisms of action have been proposed for algal inhibi-
tion of HIV including inhibition of viral entry/fusion, re-
verse transcriptase activity, and integrase and protease
activities (Ahn et al. 2004; Baba et al. 1990; Ghosh et al.
2009; McReynolds and Gervay-Hague 2007; Schaeffer and
Krylov 2000; Witvrouw and De Clercq 1997). Previously,
we reported that a high fucoidan (75%) supplement signif-
icantly amplified the CXCR4
+ hematopoietic progenitor cell
population in the circulation probably by competing with
the C-X-C chemokine receptor type 4 (CXCR4) antagonist
stromal cell-derived factor-1 (SDF-1). The CXCR4–fucoi-
dan complex resulted in blocking the expression of SDF-1
and led to the increase of the free circulating SDF-1 that
mobilized the hematopoietic progenitor cells (Irhimeh et al.
2007). Co-expression of CD4 and CXCR4 on a cell allows
HIV isolates to fuse with and infect the cell. We postulated
that fucoidan seaweed, which is characterized by its relative
large molecular weight, could bind to the T cell L-selectins
leading to the blockage of the CXCR4 receptor, thus de-
creasing the possibility for HIV to infect the cell. Our results
support this possible mechanism, providing evidence that
HIV concentrations would remain stable and gradually de-
crease over time.
Because seaweed and Spirulina are not common foods in
the USA, there is some question of whether it is even safe
for Americans with HIV to eat, and so we used traditional
drug-testing methods to demonstrate that dietary algae com-
monly eaten in other countries is safe in an algae-naïve
American population of people with HIV. The use of the
combination of a brown seaweed and a blue-green alga was
based on the improved efficacy of combination drug ARV
therapy compared to monotherapy against HIV. To test this
hypothesis, we used a pharmaceutical proof of concept test
model. Proof of Concept forms the basis for phase I early
clinical testing of drugs and is usually restricted to short (1
to 2 weeks) clinical study of up to six subjects. The end-
points are safety and any indication of efficacy. Phase II
clinical testing is used to investigate long-term toxicities,
and a minimum of 12 subjects per treatment arm has been
suggested (Julious 2005). Phase III trials are the widely
known “gold standard” of randomized placebo-controlled
clinical trials used to evaluate efficacy compared to standard
treatment, and almost always follow phase I/II testing of the
treatment.
Our dose of algae was based on the use of algae as whole
foodswithanestablishedculturalhistoryofdietaryintake.The
average daily intake of seaweed in Japan is about 5.5 g day
−1
(Matsumura 2001); anthropological estimates of Spirulina
intake in Chad are about 12 g day
−1 (Abdulqader et al. 2000)
However, we also had to estimate the maximum tolerance for
numberof pills/day peoplewould be likelyto consume, sowe
compromised on ten 500-mg capsules day
−1 of Undaria
pinnatifida sporophyll and ten 600-mg capsules day
−1 of
Spirulina. Our third arm combined both algae at half dose
(2.5gday
−1U.pinnatifidaand3g day
−1Spirulina).Although
imprecise, the dose reflected our concerns with adherence to a
supplement regimen that would be accepted by our study
subjects and still give us an indication of toxicity issues,
possible efficacy, and impact on quality of life.
Materials and methods
Subjects
This study was conducted according to the guidelines
d e s c r i b e di nt h eD e c l a r a t i o no fH e l s i n k i ,a n da l lp r o c e -
dures involving human subjects/patients were approved
by the Institutional Review Boards of the University of
South Carolina and Palmetto Health Hospital. Written
informed consent was obtained from all the subjects.
The trial is registered with the National Institutes of
Health Clinical Trials (NCT01195077) (Teas 2010).
Subjects were given an honorarium of $2/day to take
the supplements and $15/blood draw to cover the cost
of transportation to the clinic.
Inclusion criteria
Subjects were all treatment naïve, and were referred by physi-
cians to our study because of declining CD4 cell counts or
increasing viral loads. Other study criteria included no aller-
gies to seaweed, Spirulina, shellfish, or iodine and an interest
in participating in the study. Participants were instructed to
continue to eat their normal diets and vitamins, supplements,
and medications during the study. None of the subjects con-
sumed seaweed or Spirulina in either their normal diets or as
supplements. Subjects were randomly assigned to a supple-
ment treatment arm, and arms were balanced by supplement
type. At each clinic visit, supplements were provided in pre-
filled 7-day plastic containers with separate compartments for
morning and evening doses.
Blood collection and handling
Blood samples were drawn from fasting participants between
0630 and 1030 hours by venipuncture at a consistent time for
576 J Appl Phycol (2012) 24:575–582each subject at baseline and at the end of each treatment
period. Bloodsamples wereanalyzedbythe RichlandPalmet-
toHospitallab.Metabolicpanel included:glucose,blood urea
nitrogen (BUN), creatinine, BUN/creatinine ratio, sodium,
potassium, chloride, carbon dioxide, calcium, protein, albu-
min, globulin, A/G ratio, bilirubin, alkaline phosphatase
(ALP), aspartate transaminase (AST), and alanine transami-
nase (ALT). Lipid panel included total cholesterol, triglycer-
ides, high-density cholesterol (HDL), low-density cholesterol
(LDL), and very low-density cholesterol (VLDL). Complete
blood counts (CBC) with differential included: white blood
cells (WBC), red blood cells (RBC), hemoglobin (Hb), he-
matocrit (Hct), mean cell volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin concen-
tration (MCHC), red blood cell distribution width (RDW),
platelets, absolute lymphocytes, percent lymphocytes, percent
neutrophils, and percent monocytes. HIV-specific measure-
ments includedpercentCD4positiveofalllymphocytes,CD4
cells (microliters), HIV-1 RNA by PCR copies (milliliters),
and log10 HIV-1 RNA.
Undaria and Spirulina supplements
Seaweeds are consumed regularly by millions of people,
particularly in Japan and Korea. They have been approved
by the United States Food and Drug Administration and are
on the list of foods Generally Regarded as Safe (Food and
Drug Administration 1982). Spirulina received a class A
safety rating by the Dietary Supplements Information Expert
Committee of the United States Pharmacopeial Convention
(Marles et al. 2011).
Undaria pinnatifida (Harvey)Suringarwas harvested from
Bahia Bustamante on the Patagonian coast of Argentina (Sor-
iano SA). The sporophylls were removed from the stipes,
shade dried, and pulverized before encapsulation (Vicrofer
SRL, Buenos Aires, Argentina) into 500-mg capsules. The
powder was tested by Soriano SA, and the nutritional analysis
is presented in Table 1. Independent testing of the powder for
iodinewasconducted atthe IodineResearchLaboratory atthe
Boston University School of Medicine (Teas et al. 2009a, b);
fucoidan content was determined following the Stevenson
analytical method for determining algal sulfated galactans at
the Industrial Research Limited, Crown Research Institute in
Wellington, NZ (Stevenson and Furneaux 1991). Spirulina
was cultivated and harvested by Earthrise (Calipatria, CA). It
was spray dried and encapsulated into 600-mg capsules.
Earthrise
®nutrientcomposition and bioactive componentdata
for dried Spirulina were based on the Earthrise
® label. Nutri-
ent compositions of the supplements are presented in Table 1.
Medical Outcomes Study-HIV quality of life questionnaire
The Medical Outcomes Study-HIV (MOS-HIV) quality of
life questionnaire has 30 items clustered around 13 dimen-
sions of quality of life for people with HIV and has been
validated in several populations (Wu et al. 1997). The ques-
tionnaire scores were calculated using the specified scaling
and scoring program (Mapi Research Trust, Lyon, France)
and represent percent change from baseline. Subjects were
interviewed by the same project coordinator who adminis-
tered the MOS-HIV quality of life questionnaire while
Table 1 Nutrient and bioactive component composition of algal supplements compared by treatment arm
Undaria sp.
(10 capsules; 5 g)
% US dietary
value
a (%)
Spirulina
(10 capsules; 6 g)
% US dietary
value
a (%)
Combination
(10 capsules; 2.5 g
Undaria+3 g Spirulina)
% US dietary
value
a (%)
Calories 5 0 30 0 15.5 0
Carbohydrates <1 g <2 <1 g <2 <1 g <2
Protein 0.5 g <2 4 g 8 2.5 g 5
Fat 0.4 g 0 0 g 0 0.2 g 0
Dietary fiber 2.5 g 10 0.3 0 1.4 g 6
Sodium 150 mg 5 30 mg 1 90 mg 4
Potassium 270 mg 6 81 mg 2 176 mg 4
Iron 1.0 mg 5 3.4 mg 19 2.2 mg 12
Calcium 65 mg 7 6.9 mg 1 36 mg 3.5
Iodine 193 μg 129 0 0 97 μg6 4
Bioactive components associated with antiretroviral activity
10 capsules; 5 g 10 capsules; 6 g 10 capsules; 2.5 g Undaria+3 g Spirulina
Fucoidan 405 mg 0 203 mg
Phycocyanin 0 516 mg 258 mg
aPercent US daily values are based on a 2,000 calorie diet
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effects also were noted at this time.
Statistical analysis
A total of 13 subjects were recruited; data from one subject
were excluded because of inconsistent attendance at the clinic
visits and complaints about the burden of taking ten capsules/
day. Another subject dropped out of the study after the first
2 weeks, and her data also were excluded from analysis,
leaving a final sample of 11 evaluable subjects, 5 in phase I
and 6 in phase II. Nine of the subjects met the criteria of being
healthy and not yet needing ARV; two people in the phase II
trial just met the Centers for Disease Control and Prevention
(CDC) criteria for ARVand had been placed on a waiting list
for ARV. The referring physician felt that participation in our
studywouldpossiblybenefitherpatientsuntilthemedications
were available. Subjects in phase II were followed for periods
ranging from 5 to 14 months. Of these participants, one
moved out of state after 13 months, one was lost to follow-
up after 14 months, one chose a different treatment, and the
twosubjectswhohadCDC-definedAIDSwereremovedfrom
the study when their CD4 cells again decreased to below 350
cells mL
−1, and funding for ARV became available. Although
we had hoped to recruit 12 subjects in each arm, the phase II
study ended early because the referring physician left the
practice and interest in our study ceased.
Although all the study participants had HIV-related lab
tests performed, lab requests for metabolic panel, lipid pro-
file, and CBC with differential counts were not standardized
until later in the study. The number of evaluable patients for
these additional lab results therefore varied. The number for
each test is noted in Tables 2, 3, 4, 5, and 6. Lab values are
reported as means±standard error and compared with lab-
specific reference values for each endpoint. Repeated meas-
ures analyses of variance with posttest were used to deter-
mine linear trend (GraphPad Prism 5, USA). Statistical tests
were all two-tailed, and significance was set at p<0.05.
Table 2 Study population demographic and baseline HIV diagnostic
characteristics
Phase I, N011 Phase II, N06
Age (years) 38.1 (range, 26–60) 37.7 (range, 26–54)
Male 4 2
Female 7 4
African American 11 5
Latina 1 1
Average baseline
CD4 cells mL
−1
484 (range, 249 to 988) 410 (range, 264 to 522)
Average baseline
HIV1 log10
copies mL
−1
4.2 (range, 1.7 to 5.4) 4.1 (range, 3.1 to 5.1)
Table 3 Comparison of comprehensive metabolic panel results from phase I and II
Phase I Phase II Reference values
Baseline N09 3 Weeks N09 Baseline N05 3 Weeks N05 3 Months N05
Mean±SE Mean±SE Mean±SE Mean±SE Mean±SE
Glucose (mg dL
−1) 87±4 91±6
a 87±5 91±5 96±6
b 65–99 mg dL
−1
Blood urea nitrogen (BUN) (mg dL
−1) 11±1 12±1 11±1 12±2 10±1 5–26 mg dL
−1
Creatinine (mg dL
−1) 0.9±0.0 0.9±0.5 0.9±0.1 0.9±0.1 0.8±0.1 0.5–1.5 mg dL
−1
BUN/creatinine ratio 12±1 14±1 12±2 14±2 12±2 8–27
Sodium (mmol L
−1) 139±0.4 139±1 139±1 139±1 140±1 135–148 mmol L
−1
Potassium (mmol L
−1) 3.9±0.1 4.3±0.1 3.9±0.1 4.3±0.1 4.0±0.1 3.5–5.5 mmol/L
Chloride (mmol L
−1) 105±1 103±1 105±1 103±1 103±1 96–109 mmol L
−1
Carbon dioxide, total (mmol L
−1) 24±1 24±1 24±2 24±1 24±1 20–32 mmol L
−1
Calcium (mg dL
−1) 9.4±0.2 9.4±0.1 9.4±0.3 9.4±0.1 9.4±0.2 8.5–10.6 mg dL
−1
Protein, total (g dL
−1) 8.5±0.3 8.4±0.3 8.5±0.3 8.4±0.2 8.3±0.3 6.0–8.5 gdL
−1
Albumin (g dL
−1) 4.0±0.1 4.0±0.1 4.0±0.1 4.0±0.1 3.9±0.1 3.5–5.5 gdL
−1
Globulin(g dL
−1) 4.4±0.4 4.4±0.3 4.4±0.3 4.4±0.3 4.4±0.3 1.5–4.5 gdL
−1
A/G ratio 0.9±0.1 0.9±0.1 0.9±0.1 0.9±0.1 0.9±0.1 0.9–2.5
Bilirubin, total (mg dL
−1) 0.3±0.0 0.4±0.1 0.3±0 0.4±0.1 0.4±0.0 0.1–1.2 mg dL
−1
ALP (IU L
−1) 85±12 82±18 85±4 82±6 89±6 25–150 IU L
−1
AST (IU L
−1) 29±4 29±3 29±4 29±3 29±4 0–40 IU L
−1
ALT (IU L
−1) 24±5 25±5 24±5 25±6 26±9 0–40 IU L
−1
Mean±SE mean±standard error, BUN blood urea nitrogen, ALP alkaline phosphatase, AST aspartate transaminase, ALT alanine transaminase
aOne subject excluded because not fasting; n08
bOne subject excluded because not fasting; n04
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Both short- and long-term toxicity serum results suggest that
algae are nontoxic for algae-naive Americans with HIV.
Mean values for metabolic panel CBC with differential
and lipid panel results remained within reference values
(Tables 3, 4, and 5).
Data from the MOS-HIV quality of life questionnaire
indicated that subjects had improved sense of well-being
during the first 3 weeks of the study (Fig. 1). Although the
sample size was too small to do more than estimate general
trends, the magnitude of the improvement in quality of life,
as measured by subjective feelings of physical health, was
similar to that reported by subjects who were no longer
limited in vigorous activity (Wu and Rubin 1992).
Efficacy is a minor concern in phase I/II trials; there is
some evidence that algae might have decreased viral load
and increased CD4 cell counts over time (Fig. 2). This was
especially noticeable for subject 7 (Undaria plus Spirulina),
who had an increase from 474 to 714 CD4 cells μL
−1 over
the course of 13 months. This subject met the CDC criteria
for clinically significant improvement in CD4 counts (in-
crease of more than 100 CD4 cells μL
−1) and decreased
viral load (decrease of at least 0.5 log10) from 3.3 to 2.8
log10. The changes fluctuated slightly and sustained trend
over time. They reversed the declining trend seen for this
subject before enrollment in our study.
Discussion
Our clinical data further support existing in vitro and in vivo
evidence of the safety of Undaria and Spirulina (Belay
2002; Beppu et al. 2009; Chung et al. 2010; Kim et al.
2010a, b). Our sample size was too small to make any
generalizations about efficacy, but the two subjects followed
for at least a year showed either improvement or stability.
For the subject who remained stable, her life events during
that time included unemployment, family losses, and home-
lessness, all thought to contribute to social stresses associ-
ated with declining health.
Table 4 Comparison of complete blood count with differential Phase I and Phase II
Phase I, mean±MSE Phase II, mean±MSE Reference values
Baseline N010 3 Weeks N010 Baseline N05 3 Weeks N05 3 Months N05
Mean±SE Mean±SE Mean±SE Mean±SE Mean±SE
WBC (cells×10
9 L
−1) 4.8±0.5 5.1±0.5 5.1±0.9 5.4±0.9 5.0±0.8 4.0–10.5×10
9 L
−1
RBC (cells×10
12 L
−1) 4.4±0.2 4.3±0.1 4.5±0.1 4.5±0.1 4.5±0.1 4.1–5.6×10
12 L
−1
Hb (g L
−1) 128±4 129±4 131±7 133±6 136±4 115–176 gL
−1
Hct (%) 38±1 38±1 39±1.7 40±1.3 40±1.3 34–50%
MCV (fL) 88±3 89±2 87±5 88±3 90±2 80–98 fL
MCH (pg L
−1) 30±1 30±1 29±2 30±1 30±1 27–34 pg
MCHC (g L
−1) 330±3 340±3 330±10 330±10 340±0 320–360 gL
−1
RDW (%) 14.8±2 15±2 17.3±3.0 17.7±3.8 13.6±0.3 11.7–15.0%
Platelets (cells×10
9 L
−1) 259±14 244±10 269±15 253±15 249±13 140–415×10
9 L
−1
Neutrophils (%) 46±4 47±5 52±5 51±6 44±7 40–74%
Lymphocytes (%) 43±3
a 42±4
a 38±5 37±6 41±5 14–46%
Monocytes (%) 10±2 9±1 8±2 9±1 9±1 4–13%
Mean±SE mean±standard error, WBC white blood cells, RBC red blood cells, Hb hemoglobin, Hct hematocrit, MCV mean corpuscular volume,
MCH mean corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentration
aN011
Table 5 Comparison of lipid
panel results for phase II
Mean±SE mean±standard error,
HDL high-density lipoprotein,
LDL low-density lipoprotein,
VLDL very low-density
lipoprotein
Baseline, N05 3 Weeks, N05 3 Months, N05 Reference values,
mg dL
−1 Mean±SE Mean±SE Mean±SE
Total cholesterol
(mg dL
−1)
151±14 151±7 153±13 100–199
Triglycerides (mg dL
−1) 114±11 126±18 109±8 0–149
HDL (mg dL
−1) 45±6 46±6 43±6 40–59
LDL (mg dL
−1) 83±11 80±5 89±8 0–99
VLDL (mg dL
−1) 23±2 25±4 22±2 5–40
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supplements in people with HIV, but there have been a few
clinical trials conducted using Undaria sp./Alaria sp. that
support algae as nontoxic and potentially health-enhancing
for humans. Hata and colleagues reported improvements in
the blood pressure of 18 elderly Japanese patients receiving
3.3 g day
−1 additional Undaria (Hata et al. 2001). Similarly,
an 8-week study investigating the impact of consuming 4 or
6 g day
−1 of Undaria in 27 men and women reported a
significant decrease in systolic blood pressure (Teas et al.
2009a). Irhimeh compared the impact of 75% Undaria
fucoidan (3 g day
−1) on clotting time in a randomized
single-blinded placebo-controlled (guar gum) trial in 20
healthy volunteers followed for 12 days (Irhimeh et al.
2009), and the trial reported normal clinical parameters.
ClinicaldataalsoareavailableforthecloselyrelatedAlaria
esculenta. In 30 healthy postmenopausal women who con-
sumed placebo (maltodextrin) or 5 g day
−1 Alaria for 8 weeks
in conjunction with a soy supplement, there was a significant
improvement in estrogen, phytoestrogen, and insulin-like
growth factor metabolism, but no impact on thyroid function
was observed (Teas et al. 2007, 2009b, 2011).
A clinical trial of 20 people with type 2 diabetes given half
Undaria sp. and half Laminaria japonica supplement for
4 weeks improved glycemic control, lowered blood lipids,
and increased serum antioxidant activities (Kim et al. 2008).
Evidence that fucoidan has specific antiviral properties comes
from two clinical trials. In the first, 21 patients with herpes
infection consumed an Undaria high fucoidan supplement
and reported increased rates of healing and decreased reacti-
vation of viral symptoms (Cooper et al. 2002).
Perhaps of the most relevance to this study, Araya and
colleagues conducted a trial using fucoidanin13patientswith
human T-lymphotropic virus type 1-associated neurological
disease. Subjects were given 6 gday
−1 fucoidan and followed
for 6–13 months. Outcome variables were inhibition of cell-
to-cell transmission of HTLV-1 in vitro and a 42% decrease in
proviral serum concentration. The only toxicity observed was
that four patients experienced diarrhea while on fucoidan
which resolved when fucoidan treatment ceased. No effect
was observed on the host immune cells.
Several studies have included Spirulina supplements to
improve immune function in children with HIV (Simpore et
al. 2005, 2007), and it has been determined that a minimum
dose of 10 g day
−1 was needed for children (Simpore et al.
2007). As our study only provided 5 g day
−1 for adults, we
almost certainly did not give enough Spirulina to properly
test its effectiveness against HIV or its immune-enhancing
properties in people with HIV. On the other hand, the dose
(5 gday
−1) of seaweed and the combined dose of seaweed
plus Spirulina may have been synergistic and adequate to
achieve stability of immune response and viral load. More
research is needed before a therapeutic dose can be estab-
lished, especially for Spirulina.
In studies that have used the MOS-HIV questionnaire, the
same magnitude of differences (7% in general health and 5%
in mental health) distinguished people with an AIDS-defining
health event and those who remained free of opportunistic
infection (Wu et al. 1997). Although we did not collect infor-
mation on comorbidities, based on comments of participants,
part of their perceived quality of life improvements were
related to getting sick less often, and for subject 7, absence
of esophageal reflux when taking the algae supplements.
Drug development is driven nearly exclusively by financial
backing of pharmaceutical industry interests; the corollary is
Table 6 Comparison of HIV-associated lab results for phases I and II
Phase I, N011 Phase II, N06 Reference values
Baseline mean±SE 3 Weeks mean±SE Baseline mean±SE 3 Weeks mean±SE 3 Months mean±SE
Percent CD4
+ of all
lymphocytes
23±2 23±2 25±2 23±3 25±3 31–59%
CD4
+ cells μL
-1 447±47 475±65 426±48 417±50 484±67 359–1,519
HIV-1 RNA by PCR
copies/mL
61,884±24,767 50,208±25,231 28,990±17,428 58,566±46,924 18,015±7,130 2.56–3.18
Log10 HIV-1 RNA 4.34±0.23 4.26±0.21 4.02±0.30 4.10±0.36 3.89±0.32
Mean±SE mean±standard error
Percent Change from Baseline
(Mean SE)
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580 J Appl Phycol (2012) 24:575–582that a food that can be purchased in a grocery store has no
patentable possibilities. Additionally, there are cultural values
associated with algae that give it high value in some countries,
notably Japan and Korea, but low value in other countries like
the USA and Europe. Our intention had been to include 12
subjectsineachtreatmentarm.However,ourstudywaslimited
by lack of physician interest. Only one physician we
approached had any real interest in nontoxic natural alterna-
tives for her patients with HIV who showed signs of failing
health but who did not yet qualify for ARV. When she left the
community health clinic, none of her colleagues had any
interestinnon-pharmaceuticaltherapies.Intheabsenceofsuch
collaboration,wecanonlyconcludethatalgalsupplementation
appeared to be safe and improved the quality of life of the
subjects with HIV who did participate in our study, but there
may be strong physician resistance to non-pharmaceutical
alternatives for patients in resource-rich countries.
Dietary algae may offer immediate support for people
with HIV who do not have access to ARVas well as provide
new options for future drug development. Additionally,
maintaining stable health indicators, especially for people
with HIV who have declining health, may be a desirable
objective leading to prolongation of the time between HIV
infection and AIDS-defining illnesses. Based on our find-
ings and those from other clinical trials using Undaria sp. as
well as in vitro and in vivo evidence of nontoxicity, we
propose that dietary Undaria and the combination of Unda-
ria and Spirulina are safe to use in a phase III randomized
placebo-controlled clinical trial to test for efficacy against
HIV/AIDS and its associated opportunistic infections.
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